Theratechnologies Inc. (NASDAQ:THTX) is a commercial-stage biopharmaceutical company focusing on developing and commercializing innovative therapies. Despite facing challenges, THTX continues to compete effectively in the biopharmaceutical industry.
On July 9, 2025, THTX reported an earnings per share (EPS) of -$0.01, aligning with the estimated EPS. However, the company generated a revenue of $17.7 million (three months ended May 31), below the expected $24.3 million, highlighting the challenges THTX faces in meeting market expectations.
Despite the revenue shortfall, Theratechnologies achieved a revenue of $36.8 million for the first half of the fiscal year. This marks the fifth consecutive quarter of positive adjusted EBITDA, indicating some operational efficiency. The company's entry into a definitive agreement to be acquired by an affiliate of Future Pak is a significant development.
The demand for THTX's product, EGRIFTA SV®, remains strong, with record high patient enrollments. Although the company faced an estimated negative impact of $10 to $12 million due to a shortage of EGRIFTA SV® in the first quarter, this issue has been resolved. Patient numbers have returned to normal levels, and new patient enrollments continue to grow.
THTX's financial metrics reveal some challenges. The company has a negative price-to-earnings (P/E) ratio of -41.8, indicating negative earnings. Its price-to-sales ratio is about 1.63, and the enterprise value to sales ratio is around 2.15. The enterprise value to operating cash flow ratio is approximately -32.73, reflecting negative operating cash flow. The debt-to-equity ratio is approximately -2.06, indicating a negative equity position. However, THTX has a current ratio of about 1.08, suggesting a modest level of short-term financial health.
